Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, RBITC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-20197R-RBITC-100uL |
| Product Name | Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, RBITC Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Specificity | This phosphorylation site is homologous in the listed cross reactive species at the specified location. |
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Cow, Chicken, Rabbit |
| Specifications | |
| Conjugation | RBITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human OPRD1 around the phosphorylation site of TP(p-S)DG |
| Modification Site | Ser363 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 4985 |
| Swiss Prot | P41143 |
| Subcellular location | Cell membrane |
| Synonyms | OPRD; Delta-type opioid receptor; D-OR-1; DOR-1; OPRD1 |
| Background | G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, RBITC Conjugated (bs-20197R-RBITC) validated for, and at what dilution?
bs-20197R-RBITC is validated for WB (1:300-5000); FCM (1:20-100); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, RBITC Conjugated (bs-20197R-RBITC) react with?
Tested reactivity: Human, Mouse, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Cow, Chicken, Rabbit.
How should bs-20197R-RBITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, RBITC Conjugated (bs-20197R-RBITC)?
KLH conjugated synthetic peptide derived from human OPRD1 around the phosphorylation site of TP(p-S)DG
What are the excitation and emission wavelengths of the RBITC conjugate (bs-20197R-RBITC)?
RBITC on bs-20197R-RBITC: excitation / emission 540nm/625nm.